Post-Ozempic Weight Retention: A Mixed Bag

A recent analysis indicates that individuals who stop using medications similar to Ozempic manage to retain roughly 25% of the weight they lost for up to a year. However, the key detail remains: it’s unclear how much of this weight is muscle versus fat.

This situation points to a significant gap in understanding the impact of drugs like semaglutide and tirzepatide, often prescribed for managing type 2 diabetes or weight. Initial studies hint that around 40 to 60% of the weight loss during these treatments could be from lean muscle mass.

While it’s widely recognized that patients often regain weight after halting these medications, the specific composition of this regained weight isn’t fully known.

“If the weight regained is mostly fat, individuals might find themselves in a worse position concerning their fat-to-lean mass ratio, which could have negative health implications,” shares medical researcher Brajan Budini from the University of Cambridge, who is a co-author of the study.

The study provides a thorough review of post-treatment weight gain and models its progression for up to 52 weeks post-cessation.

Weight management post-treatment is crucial, especially given that over a billion individuals worldwide struggle with obesity. GLP-1 drugs have shown remarkable effectiveness, often helping people achieve weight losses of 20% or more.

These medications mimic a natural hormone that regulates blood sugar and decreases appetite. Nevertheless, due to side effects, high costs, and prescription challenges, nearly half of users discontinue GLP-1 drugs within the first year.

“Medications like Ozempic and Wegovy work as appetite suppressants, allowing individuals to feel full sooner, which contributes to weight loss,” says Budini. “Once they stop taking these medications, it’s akin to taking their foot off the brake, leading to swift weight regain.”

To better understand weight regain, researchers analyzed 48 relevant studies. It quickly became apparent that many studies had limitations, such as tracking patients only for a few weeks or significant variability in follow-up timing after medication cessation. Overall, the authors note that post-GLP-1 weight gain is “largely underexplored in the literature.”

The researchers opted for a selection of high-quality studies that met specific requirements: they needed to be randomized, involve over 100 participants, report a minimum weight loss of 3 kilograms (6.6 pounds), and include at least one follow-up check-up 12 weeks after stopping medication.

This led them to a systematic review focused on just six randomized controlled trials (RCTs) with a combined total of more than 3,200 participants, tracking them for up to 52 weeks after stopping weight-loss drugs.

The findings highlighted a rapid initial weight regain that gradually slowed down after stopping the medications. A year post-treatment, participants had regained 60% of the lost weight.

The researchers then utilized this data to project outcomes beyond 52 weeks, estimating that weight regain stabilizes at 60 weeks and that patients could regain around 75% of their initial weight loss. But why does this happen?

There’s a possibility that the medications help patients develop healthier eating habits or induce physiological changes that impact hormone levels or even hypothalamic function.

However, it’s worth noting that a significant portion of lost weight could be muscle, and it’s unclear if lean mass recovers at the same pace as fat mass post-treatment. Additionally, newer drugs like semaglutide and tirzepatide might lead to greater weight reductions but are not as effective in preserving lean mass.

Considering this, implementing prescription strategies that gradually reduce doses could assist patients in maintaining fat loss. It’s equally beneficial for healthcare providers to encourage healthy eating and exercise, both vital for lasting wellbeing.

“Providing guidance on improving diet and exercise habits is essential, rather than relying exclusively on medications,” concludes research co-author Steven Luo.

This study is published in eClinicalMedicine.